Keywords: STEMI Guidelines, AstraZeneca, Brilinta, Eli Lilly, Effient

STEMI guidelines now recommend AstraZeneca's ticagrelor as first-line treatment option

Article | 30 August 2012

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that ticagrelor, its oral antiplatelet medicine, marketed by the company as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in